secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inhibikase Therapeutics, Inc. (IKT)
CIK:        0001750149
Form:       8-K
Filed at:   2022-03-24T23:59:59+00:00
Accession:  0001193125-22-083462
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Inhibikase presents Phase 1/1b data at AD/PD 2022; no numerical results in 8-K
------------------------------------------------------------------------------

- Company presented Phase 1 and 1b clinical study results at AD/PD Conference in Barcelona on March 18, 2022.
- Presentation focuses on Abl-kinase inhibition (IKT-148009) for Parkinson's disease modification.
- No specific quantitative outcomes, milestones, or financial impact disclosed in the filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1750149/000119312522083462/0001193125-22-083462-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1750149/000119312522083462/d320841d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-083462

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer